Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.
This study, called KARCHeR-1, is investigating a new approach for treating liver cancer (hepatocellular carcinoma), which is a common and serious cancer. Currently, surgery is the best cure, but it's not always possible, and the cancer can sometimes come back. Researchers are testing if a special type of targeted radiation, called SBRT, given before surgery can improve outcomes. SBRT is known to destroy cancer cells. The main goal of this first phase study is to check if this combined treatment is safe and practical. They want to make sure it doesn't cause significant delays to surgery or serious side effects, as this is a new treatment idea. If it proves safe, further studies will look at how well it works.
At a glance
What is this study about?
Liver cancer, known medically as hepatocellular carcinoma (HCC), is a serious illness. While surgery can be a cure for some, it's not suitable for everyone, and unfortunately, the cancer can sometimes return after surgery. This is often because tiny cancer cells, too small to see, might be left behind around the main tumour.
Doctors have a treatment called Stereotactic Body Radiation Therapy (SBRT), which uses very focused radiation to safely destroy or shrink cancer cells without surgery. Researchers in this study have a new idea: what if they use SBRT *before* surgery for liver cancer? The hope is that this radiation treatment could get rid of those tiny hidden cancer cells around the main tumour, potentially making surgery more effective and reducing the chance of the cancer coming back.
Because this is a new approach, the most important first step is to check if it's safe and practical. This study, called KARCHeR-1, will involve about 30 patients. The main aim is to see if giving SBRT before surgery causes any major problems, such as serious side effects or delays that might stop someone from having their planned surgery. If the treatment is found to be safe and doesn't cause these issues, it opens the door for future studies to find out how well it works to treat liver cancer long-term.
Key takeaways
- This study is testing a new combination treatment for liver cancer.
- It involves targeted radiation (SBRT) before standard liver surgery.
- The main goal is to check if this combined approach is safe and practical.
- It aims to potentially improve surgery results by targeting tiny cancer cells.
- About 30 patients will take part in this early-stage research.
Who may be eligible?
To be considered for this study, you would need to have liver cancer (hepatocellular carcinoma) that has been confirmed by a sample (biopsy) or meets specific medical guidelines. The cancer should be a single tumour measuring between 3 and 8 centimetres, and your doctors must believe that it can be completely removed by standard surgery.
There are also reasons why someone might not be able to join. For example, if you have other serious health problems that would make surgery or radiation unsafe, or if your liver disease is very advanced (known as decompensated cirrhosis). You also wouldn't be able to join if the cancer has spread to other parts of your body, or if you've had other cancer treatments in the last five years.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do I have a confirmed diagnosis of liver cancer (HCC)?
- Is my liver tumour a single spot between 3 to 8 centimetres in size?
- Am I considered suitable for standard liver surgery to remove the tumour?
- Do I have good general health and liver function?
- Have I not had other cancer treatments within the last 5 years?
What does participation involve?
If you decide to take part in this study, you will first receive a special type of targeted radiation therapy (SBRT). This will involve several treatment sessions over a short period. After the radiation, you will have surgery to remove the liver tumour, as planned by your doctors. Throughout this process, you will have regular hospital visits for check-ups, blood tests, and scans to monitor your health and how the treatment is working. Doctors will carefully watch for any side effects and ensure your recovery is going well after surgery. The study will also involve following up on your health and any return of the cancer for a number of years after your treatment.
Potential risks and benefits
Locations (1)
- Hop Claude Huriez Chu LilleVerified postcodeLille, France· Recruiting
Common questions
What is hepatocellular carcinoma (HCC)?
It's the most common type of liver cancer, often linked to long-term liver damage.
What is SBRT?
SBRT is a focused radiation treatment that precisely targets and destroys cancer cells with high doses, saving healthy tissue.
Why combine SBRT with surgery?
The idea is that SBRT might destroy tiny cancer cells around the main tumour before surgery, making the surgery more effective.
How many people are in this study?
This early study plans to include about 30 patients to check the safety and practicality of the new treatment.
What happens if there are problems?
The study will stop early if too many patients experience major delays to surgery or serious side effects.
How to find out more
Emmanuel Boleslawski, MD,PhD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.